{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for acetohydroxamic root_protein_modifications_structuralModifications_molecularFragment_refPname in Protein Structural Modification Substance Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M012
(2024)
Source URL:
First approved in 2024
Source:
M012
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
GOHIBIC by InflaRx GmbH
(2023)
Source URL:
First approved in 2023
Source:
GOHIBIC by InflaRx GmbH
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Sotrovimab by GlaxoSmithKline LLC
(2021)
Source URL:
First approved in 2021
Source:
Sotrovimab by GlaxoSmithKline LLC
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA761158
(2020)
Source URL:
First approved in 2020
Source:
BLA761158
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
24hr Health Glow by USA Health
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
21 CFR 355
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
HERBALIFE SKIN 7 DAY RESULTS KIT
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Conditions:
Status:
Possibly Marketed Outside US
Source:
Laser Rejuvenation restoring damage skin by Universal Cosmetic Co., Ltd
Source URL:
First approved in 2003
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
ACETYL HEXAPEPTIDE-8 (ARGIRELINE®), a hexapeptide Ac-EEMQRR-NH2, is an anti-wrinkling agent. It significantly inhibits neurotransmitter release with a potency similar to that of botulinum toxin. ACETYL HEXAPEPTIDE-8 (ARGIRELINE®) is a mimic of the N-terminal end of SNAP-25 which competes with SNAP-25 for a position in the SNARE complex, thereby modulating its formation. If the SNARE complex is slightly destabilized, the vesicle can not release neurotransmitters efficiently and therefore muscle contraction is attenuated, preventing the formation of lines and wrinkles.
Status:
Possibly Marketed Outside US
Class:
PROTEIN
